Although the use of PARP inhibitors represents the first instance to exploit synthetic lethality in pancreatic cancer, their use is by nature limited by (1) the relatively low occurrence of mutations in BRCA genes [8] and (2) inevitable and frequent drug resistance [78]. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.